You’d think the price of a cancer drug would be tied to how much longer it helps people live. But it’s not. This isn’t just an opinion; study after study has shown it. A major analysis found almost no connection between the monthly cost of new cancer drugs and their actual survival benefits. Another study examining drugs approved in Europe found that many hit the market without clear evidence that they meaningfully extended life or improved its quality.
Let that sink in for a moment.
We’re not talking about a few rare cases here. We’re talking about a consistent pattern: drugs that cost over $100,000 a year often only give patients a few extra weeks or months. Even when major cancer organizations use their own value scales to score new drugs, a huge number of them fall short of what they’d call a “meaningful clinical benefit.”
And still, the prices keep going up.
Between the early 2000s and today, the average launch price of a new cancer drug in the U.S. has more than tripled, even after adjusting for inflation. Now, it’s normal for a new therapy to start at $150,000 a year, and when you start combining drugs, that can easily push past $200,000.
So if the price isn’t based on survival, what is it based on?
This is where it gets uncomfortable. It’s based on hope.
Not on survival charts or clinical trial data. It’s based on the hope that this drug might just work better for you than it did for the average person in the study. The hope that your outcome won’t be defined by a median. The hope that doing something—anything—is better than doing nothing.
Hope is essential in fighting cancer. But it has also become, very quietly, a key part of how these drugs are priced.
Because cancer isn’t a normal market. Patients aren’t behaving like typical consumers. They’re making life-or-death decisions under incredible emotional pressure, with no real way to weigh the trade-offs. In that environment, what are you willing to pay? Almost anything.
The result is a broken system where: Drugs that offer a few extra months of life can command six-figure prices. Many treatments get approved based on early indicators, with the real proof of survival benefit being modest or still unknown. And insurers are under immense pressure to cover it all, no matter how uncertain the value.
This isn’t an attack on innovation. When a drug offers a real breakthrough—years of extra life, or even a cure—it absolutely should be rewarded. But that’s not what we’re consistently paying for. We are often paying a fortune for a marginal gain, because the alternative—saying no in the face of cancer—feels morally impossible.
And that’s the tension no one wants to deal with. If the price isn’t anchored to survival or quality of life, what is it anchored to? Right now, it seems to be anchored to how much hope costs.
And that isn’t just a problem for our wallets. It’s a problem with the entire system.

